FDA, Industry Agree On Working Groups To Support User-Fee Negotiations
This article was originally published in The Gray Sheet
The agency and industry agreed to create working groups allowing subject-matter experts to delve deeper into technical details on some of the key proposals raised thus far in user-fee reauthorization talks. Areas of focus include de novo reviews, pre-submissions and personnel recruitment challenges.
You may also be interested in...
Device industry groups significantly pared down their review-process reform proposals for the next user-fee program at a meeting with FDA last month. To lower the price tag, they expunged more than a dozen ideas that have been raised by companies or the agency at prior meetings. But FDA sees a lot of important priorities missing in industry's latest five-point plan.
After months of negotiations, the agency has proposed hiring new staff and making significant changes to their device review process that would cost $500 million – on top of current user fee revenues – and does not account for inflation.
The Senate confirmed Robert Califf as the new FDA commissioner after months of delay, giving the cardiologist, clinical trial expert and established agency official a better platform to push his priorities, which include combination product and clinical data-collection reforms, while implementing projects already under way.